


13. (Amended) A compound of Claim [7] 1 wherein Z is H,  $R=R_4=R_1=R_2=R_5=H$ , and  $R_3$  is alkyl having 1-4 carbon atoms.

14. (Amended) A compound of claim [7] 1 wherein Z is CH,  $R=R_4=R_1=R_3=R_5=H$ , and  $R_2$  is alkyl having 1-4 carbon atoms.


15. (Amended) A compound of claim [7] 1 wherein Z is CH,  $R=R_4=R_3=R_2=R_5=H$ , and  $R_1$  is alkyl having 1-4 carbon atoms.

20. (Amended) An (S)-enantiomer compound [of claim 7] having the formula:



a salt thereof with a pharmaceutically acceptable acid or a pharmaceutically acceptable complex thereof.


21. (Amended) An (S)-enantiomer compound [of claim 7] having the formula:



a salt thereof with a pharmaceutically acceptable acid or a pharmaceutically acceptable complex thereof.

AS  
Control  
22.


(Amended) An (S)-enantiomer compound [of claim 7] having the formula:



a salt thereof with a pharmaceutically acceptable acid or a pharmaceutically acceptable complex thereof.

24.


(Amended) An (R) enantiomer compound [of claim 7] having the formula:



a salt thereof with a pharmaceutically acceptable acid or a pharmaceutically acceptable complex thereof.

25.

(Amended) An (R)-enantiomer compound [of claim 7] having the formula:



a salt thereof with a pharmaceutically acceptable acid or a pharmaceutically acceptable complex thereof.

#### REMARKS

Claims 1-22 and 24-25 are pending in the present reissue application. Claims 1-3, 5, 7-9, 11 and 16-19 were previously issued and are not being amended in this preliminary amendment. Claim 23 is being cancelled and Claims 4, 6, 10, 12-15 and 20-25 are being amended in this preliminary amendment. Support for the amendments to these claims can be